Perioperative Chemoradiotherapy May Improve Survival in Urethral Carcinoma
the Cancer Therapy Advisor take:
Patients who received neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy for cT3 and/or cN+ primary urethral carcinoma (PUC) appeared to demonstrate improved survival compared with those who underwent upfront surgery with or without adjuvant chemotherapy, a recent study published online in the journal Annals of Oncology has shown.
For the study, researchers sought to assess the effect of perioperative chemo(radio)therapy) in patients with advanced PUC. Researchers identified 124 patients who were diagnosed and underwent surgery for PUC between 1993 and 2012.
Results showed that the objective response rate was 25% and 33% for neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy, respectively.
For patients who achieved an objective response to neoadjuvant treatment, the 3-year overall survival was 100% for those who received neoadjuvant chemotherapy and 58.3% for those who received neoadjuvant chemoradiotherapy (P = 0.30).
In the locally advanced subset of patients, the 3-year overall survival was 100% for those who received neodjuvant chemotherapy, 100% for those who received neoadjuvant chemotherapy, 50% for those who underwent surgery alone, and 20% for those who underwent surgery plus adjuvant chemotherapy (P = 0.016).
The study demonstrated a significant association between neoadjuvant treatment and improved 3-year relapse-free survival (P = 0.022) and overall survival (P = 0.022).
Patients who received neoadjuvant chemotherapy for primary urethral carcinoma appeared to demonstrate improved survival.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
- Age-adjusted Comorbidity Predicts Survival in Laryngeal Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Role of miR-125a-5p Clarified in Bladder Cancer